Slingshot Insights

Catalyst

Slingshot members are tracking this event:

PTI-428 Phase I topline proof of concept data in CF patients expected in Q2 2017

Source Link:: http://ir.proteostasis.com/phoenix.zhtml?c=254052&p=irol-newsArticle&ID=2257752

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

PTI

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details company scientists will present data from its ongoing Phase 1 clinical trials studying PTI-428 in subjects with CF and healthy volunteers at the 30th Annual North American Cystic Fibrosis Conference (NACFC).

http://ir.proteostas...

Additional Relevant Details Update on Mar 30 2017: Initially expected by year end 2016, data has beeen rescheduled for release Q2 2017.

http://ir.proteostas...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 29, 2017

Occurred Source:

http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-reports-preliminary-data-phase-1-study

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Cystic Fibrosis, Pti-428, Dysfunctional Protein Processing, Protein Activity In Vitro, Cftr Mrna Expression